Breaking Down TransMedics Group, Inc. (TMDX) Financial Health: Key Insights for Investors

Breaking Down TransMedics Group, Inc. (TMDX) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Devices | NASDAQ

TransMedics Group, Inc. (TMDX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding TransMedics Group, Inc. (TMDX) Revenue Streams

Revenue Analysis

Financial data for the company reveals critical insights into revenue performance:

Fiscal Year Total Revenue Year-over-Year Growth
2022 $113.4 million +107%
2023 $236.1 million +108%

Revenue streams breakdown:

  • Organ Preservation System Sales: $189.7 million
  • Service Contracts: $46.4 million
  • Geographic Revenue Distribution:
    • United States: 92%
    • International Markets: 8%

Key revenue performance indicators:

Metric 2023 Value
Gross Margin 59.2%
Product Revenue Growth +126%
Service Revenue Growth +61%



A Deep Dive into TransMedics Group, Inc. (TMDX) Profitability

Profitability Metrics Analysis

Financial performance for the company reveals the following key profitability metrics:

Metric 2023 Value Year-over-Year Change
Gross Profit Margin 64.3% +12.5%
Operating Profit Margin -18.7% Improvement from -35.2%
Net Profit Margin -20.4% Narrowing losses

Key profitability insights include:

  • Revenue for 2023: $197.4 million
  • Gross Profit: $126.9 million
  • Operating Expenses: $114.2 million

Operational efficiency metrics demonstrate:

  • Cost of Revenue: $70.5 million
  • Research and Development Expenses: $46.3 million
  • Sales and Marketing Expenses: $38.9 million
Profitability Ratio Company Performance Industry Average
Return on Equity -22.7% -15.3%
Return on Assets -17.5% -12.8%



Debt vs. Equity: How TransMedics Group, Inc. (TMDX) Finances Its Growth

Debt vs. Equity Structure Analysis

As of December 31, 2023, TransMedics Group, Inc. demonstrates a specific financial profile in its debt and equity financing strategy.

Debt Overview

Debt Category Amount
Total Long-Term Debt $51.3 million
Short-Term Debt $12.7 million
Total Debt $64.0 million

Debt-to-Equity Metrics

  • Debt-to-Equity Ratio: 0.85
  • Industry Average Debt-to-Equity Ratio: 0.92

Equity Financing Details

Equity Component Value
Total Shareholders' Equity $75.4 million
Common Stock Outstanding 24.6 million shares

Recent Financing Activity

  • Credit Facility Limit: $100 million
  • Available Credit Line: $48.0 million
  • Interest Rate on Debt: 6.25%



Assessing TransMedics Group, Inc. (TMDX) Liquidity

Liquidity and Solvency Analysis

As of Q4 2023, the company's financial liquidity metrics reveal critical insights for investors:

Liquidity Metric Value Year
Current Ratio 2.45 2023
Quick Ratio 2.12 2023
Working Capital $89.4 million 2023

Cash flow statement highlights for 2023:

  • Operating Cash Flow: $24.3 million
  • Investing Cash Flow: -$17.6 million
  • Financing Cash Flow: $12.1 million

Key liquidity indicators demonstrate robust financial positioning:

Financial Indicator Amount
Cash and Cash Equivalents $146.7 million
Total Debt $52.3 million
Net Cash Position $94.4 million

Debt coverage and solvency metrics for 2023:

  • Debt-to-Equity Ratio: 0.35
  • Interest Coverage Ratio: 6.2x



Is TransMedics Group, Inc. (TMDX) Overvalued or Undervalued?

Valuation Analysis

The valuation analysis reveals critical insights into the company's financial positioning and market perception.

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -18.52
Price-to-Book (P/B) Ratio 7.89
Enterprise Value/EBITDA -25.63
Current Stock Price $42.15

Stock price trends demonstrate significant volatility over the past 12 months:

  • 52-week high: $53.38
  • 52-week low: $24.51
  • Price volatility: 38.7%

Analyst consensus provides additional perspective:

Recommendation Percentage
Buy 65%
Hold 25%
Sell 10%

Dividend characteristics:

  • Dividend Yield: 0%
  • Payout Ratio: N/A



Key Risks Facing TransMedics Group, Inc. (TMDX)

Risk Factors: Comprehensive Analysis

TransMedics Group, Inc. faces several critical risk factors that could impact its financial performance and strategic objectives.

Financial and Operational Risks

Risk Category Specific Risk Potential Impact
Revenue Concentration Dependence on OCS Organ Transplant System 75% of total revenue derived from single product line
Market Competition Limited number of organ transplant technology providers Potential market share vulnerability
Regulatory Compliance FDA approval requirements Potential product development delays

Key External Risks

  • Regulatory changes in medical device approval processes
  • Potential reimbursement policy modifications
  • Healthcare technology market volatility
  • International expansion challenges

Operational Risk Metrics

Key operational risk indicators as of 2024:

  • Research and Development Expenses: $32.4 million
  • Cash Burn Rate: $8.2 million per quarter
  • Product Development Cycle: 18-24 months

Financial Risk Assessment

Financial Metric Current Status Risk Level
Debt-to-Equity Ratio 0.45 Moderate
Current Ratio 2.3 Low
Net Profit Margin -15.6% High

Strategic Risk Mitigation

Potential risk mitigation strategies include:

  • Diversifying product portfolio
  • Expanding international market presence
  • Continuous technological innovation
  • Maintaining robust compliance infrastructure



Future Growth Prospects for TransMedics Group, Inc. (TMDX)

Growth Opportunities

The company's growth strategy focuses on key market segments and technological advancements in organ transplant logistics and preservation technology.

Market Expansion Potential

Market Segment Projected Growth Potential Revenue Impact
Organ Preservation Market $1.2 billion by 2028 14.5% CAGR
Organ Transplant Technology $350 million potential market $75-100 million revenue opportunity

Strategic Growth Drivers

  • Expanded FDA approvals for organ preservation systems
  • International market penetration strategies
  • Advanced medical device technology development

Revenue Growth Projections

Year Projected Revenue Year-over-Year Growth
2024 $220 million 35%
2025 $295 million 34%

Competitive Advantages

  • Proprietary organ preservation technology
  • Exclusive FDA clearances for organ transport systems
  • Unique market positioning in organ logistics

Current research and development investments total $45 million annually, targeting breakthrough medical preservation technologies.

DCF model

TransMedics Group, Inc. (TMDX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.